

# Physicians' workload slows benefits admin

*Helping doctors at point of prescribing will save pharmacists aggravation*


One key stakeholder group often overlooked in the provision of the employer-sponsored drug plan benefit is physicians. Loaded up with paperwork by the insurers, pharmacy benefit managers (PBMs) and benefits consultants, Canadian doctors face an ever-increasing administrative burden on daily practice related to private drug plans, while their numbers continue to dwindle.

A general shortage of physicians, especially family physicians, has left many areas designated

"underserved." Medical schools have not been graduating enough physicians to meet current patient population demands. Faced with student loan debts, new graduates have shied away from family practice, with overhead and start-up costs, preferring instead the flexibility and income of emergency room and locum work.

In 2003, only 25% of medical residents selected family practice; that's down from 44% in 1992. Simply put, there are not enough physician-hours to meet patient needs. With practices in underserved areas already bursting at the seams, physicians have closed them off to new patients, leaving thousands without a family doctor.

Already overworked and stressed, the few family doctors still practising have seen the mountain of paperwork continue to grow. Forms for life insurance, long-term disability claims, WSIB claims, CCAC applications, motor vehicle accidents, etc. all take time away from patient care. Add to those the required forms for employee benefits such as physiotherapy, massage therapy and custom



## PAYER ISSUES

by Chris von Heymann

orthotics, and one can appreciate doctors' resistance to the extra work caused by complex drug benefit plans.

Multiple customized formularies, prior authorization programs (each with different criteria and forms), tiered copayments, annual/lifetime maximums ... it's hard to keep it all straight.

Many would argue that it's not the doctors' responsibility to keep it all straight; they are clinicians, whose job is to take care of the

health of their patients (sound familiar?) and, where necessary, to prescribe the most appropriate drug therapy, not to match their prescribing practices to plan sponsors' requirements.

Yet, these drug plan management processes are important to ensure the responsible use of the benefit. Without them, its long-term sustainability for employers may be in jeopardy.

It's been argued that the most efficient way to ensure a prescribed product matches the benefit is to influence behaviour at the point of prescribing. Ensuring the physician prescribes a product that is best covered by the patient's plan, the first time, will save pharmacists, physicians and patients alike a time-consuming phone call or fax requesting a prescription change.

With progress in technology, there have been some suggestions for point-of-prescribing tools to facilitate access to plan-coverage information in the physician's office. However, this is still some time away, as coordinating the involvement of the insurers, PBMs, software and hardware developers, and others proves to be a major hurdle.

What, then, can pharmacists do to help physicians with this selection process?

### A SUGGESTION FOR NOW

Take the lead and organize a local information session through your pharmacy. Invite a human resources representative from a major local employer, the company's benefits consultant, area physicians, and pharmacists and pharmacy technicians.

Ask your HR contact and/or their benefits consultant to present the particulars of the company's drug plan, including plan description, inclusion/exclusion decisions, as well as current utilization and cost drivers.

Open the floor and moderate a discussion to identify frustrations in practice related to plan administration, both in the physicians' offices and in the pharmacy. Get the group to agree on steps to reduce these frustrations, such as providing plan summary cards for each patient chart. Identify ways the pharmacy can simplify or expedite any paper-processing and/or drug product selection for the physicians.

While such an initiative is more feasible for smaller areas with a limited number of major employers, it should also be considered in larger urban centres for pharmacies that draw a large number of employees from the same employer. 🍁

*Chris von Heymann is a principal with Cubic Health Inc., a drug plan management consulting firm based in Toronto, and continues to practise pharmacy part-time in the community.*

## CONGRATULATIONS TO THE WINNERS!



# PRIX GALIEN CANADA 2004

*Celebrating excellence in Canadian pharmaceutical research*

## THE PRIX GALIEN CANADA AWARDS FOR EXCELLENCE IN PHARMACEUTICAL AND BIOTECHNOLOGICAL RESEARCH

The Prix Galien awards are prestigious annual prizes recognizing and promoting research and innovation in the pharmaceutical and biotechnology fields. Considered by the pharmaceutical industry as the equivalent of a Nobel Prize, a Prix Galien award is one of the highest tokens of recognition in pharmaceutical R&D.

### THE 2004 WINNERS

#### PRIX GALIEN CANADA AWARD

##### INNOVATIVE DRUG PRODUCT

Spiriva (tiotropium bromide monohydrate), a drug marketed by Boehringer Ingelheim Canada Ltd.

#### PRIX GALIEN CANADA AWARD

##### RESEARCH

Dr. Paul Armstrong, Professor of Medicine, University of Alberta, for his devoted efforts to improve the care of people suffering from acute heart disease.

#### PRIX GALIEN CANADA AWARD

##### BIOTECHNOLOGY

Ecopia Biosciences Inc., for its remarkable R&D achievements.

#### BELLEAU-NICKERSON PRIZE

This prize, recognizing drugs that have made major pharmacological, social and economic contributions, went jointly to Rescriptor (delavirdine mesylate) from Pfizer, Retrovir (also known as AZT or Zidovudine) from GlaxoSmithKline, and Invirase (saquinavir mesylate) from Roche.

#### OUR PARTNERS :



**ASSOCIATION**  
Canada's pharmaceutical R&D companies

#### UNIVERSITÉS

University of Alberta  
University of British Columbia  
University of Calgary  
Dalhousie University  
Laval University  
University of Manitoba  
McMaster University  
Memorial University of Newfoundland  
McGill University  
University of Montreal  
University of Ottawa  
Queen's University  
University of Saskatchewan  
University of Sherbrooke  
University of Toronto  
University of Western Ontario

#### 2003

Gleevec (mesylate d'imatinib), Novartis  
Dr. Mark Wainberg of the McGill University AIDS Centre, McGill University, for his laboratory and in-field work to prevent the spread of AIDS.

#### 2002

ENBREL (étanercept), Wyeth-Ayerst inc.  
Dr. Anthony Pawson, Samuel Lunenfeld Research Institute, Toronto, and Dr. Julia Levy and Dr. David Dolphin, University of British Columbia.

#### 2001

Vlagra (sildénafil), Pfizer  
Dr. Salim Yusuf, McMaster University, for his major contributions in the heart disease field.

#### 2000

Singulair (montélukast sodique), Merck Frosst  
The team that discovered and developed montelukast sodium.

#### 1999

LIPITOR (atorvastatine), Pfizer  
Dr. Jack Hirsh, Director, Hamilton Civic Hospital, for his research on the treatment of venous thrombosis.

#### 1998

Fosamax (Alendronate), Merck Frosst  
Dr. D. L. J. Lorne Tyrell, University of Alberta, and Dr. M. J. Robins, University of Utah, for their work on the hepatitis B virus.

#### 1997

3TC / Epivir (lamivudine), Shire Biochem/GlaxoSmithKline  
Drs. S. Gauthier, J. Poirier and R. Quirion, Douglas Hospital, Montreal, for their study on the therapeutic perspectives of Alzheimer Disease.

#### 1996

Sabril (vigabatrine), Aventis  
Dr. Gervais Dionne and the Biochem Pharma team for their discovery of lamivudine (3TC).

#### 1995

RISPERdal (rispéridone), Janssen-Ortho  
Dr. Peter Schiller, Montreal Clinical Research Institute, for his research on peptide neurotransmitters.

#### 1994

Imitrex (sumatriptan), GlaxoSmithKline  
Dr. P. Seeman, Dr. H. VanTol and Dr. H. Niznik, University of Toronto, for their work in identifying dopaminergic receptors.